FN2 Earnings Intelligence

Takeda Pharmaceutical Company Limited earnings overview

Latest Takeda Pharmaceutical Company Limited (TAK) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.

Next reportTakeda Pharmaceutical Company Limited reports Thursday, Oct 29, 2026 · Before market openConsensus EPS $0.14 · consensus revenue $7.34B
TAK FY2026 Q2 · Calendar Q4 2026

Takeda Pharmaceutical Company Limited

Takeda's current analysis supports a measured growth-transition story: new launches and late-stage pipeline progress are advancing, while transformation savings are offsetting modest core-revenue pressure. The evidence is constructive but execution, access and mature-portfolio risks remain material.

EPS surprise—
Market move-1.0%

Get the TAK recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.